Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Interactions between Antidepressants and Warfarin: A Review

Author(s): Sukru Alperen Korkmaz*, Tekin Guney, Imdat Dilek and Ali Caykoylu

Volume 16, Issue 3, 2020

Page: [194 - 204] Pages: 11

DOI: 10.2174/2666082216999200622135657

Price: $65

Abstract

Background: Since warfarin has a very narrow therapeutic index, the interaction between warfarin and antidepressants is very critical and has potentially severe consequences. It is unclear whether clinicians have sufficient knowledge about the risk of bleeding when warfarin and antidepressants are used concomitantly.

Objective: In this systematic review, we discuss the main considerations when using warfarin with antidepressants.

Methods: The information about warfarin-antidepressant interactions was obtained from Google Scholar®, PubMed/MEDLINE® and a hand search of the published literature. The following research terms which were systematically combined with each other to find articles: warfarin, anticoagulant, interactions, antidepressant (and each antidepressant name individually), SSRI, SNRI, TCA, MAOI.

Results: Several possible mechanisms that can cause bleeding when antidepressants and warfarin are used concomitantly, have been discussed. According to the available data, sertraline and citalopram/ escitalopram are safer antidepressants to use with warfarin, whereas fluoxetine and fluvoxamine have a higher interaction potential with warfarin. The remaining antidepressants appear to lie somewhere in between and have little empirical data to guide the clinicians.

Conclusion: It is recommended that when an antidepressant is prescribed to a patient using warfarin, patient’s international normalized ratio (INR) level should be checked regularly. In this review, the interaction between warfarin and antidepressants, including new ones, were evaluated inclusively and in detail.

Keywords: Anticoagulant, antidepressant, cytochrome, interaction, SSRI, SNRI, warfarin.

« Previous Next »
Graphical Abstract

[1]
Jeffrey IW. Antithrombotic drugs Hematology: basic principles and practice. 6th ed. Philadelphia, PA, USA: Elsevier 2013; pp. 2102-19.
[2]
Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24(12): 1668-74.
[http://dx.doi.org/10.1592/phco.24.17.1668.52338] [PMID: 15585436]
[3]
Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149(8): 1785-9.
[http://dx.doi.org/10.1001/archinte.1989.00390080059014] [PMID: 2788396]
[4]
Hance M, Carney RM, Freedland KE, Skala J. Depression in patients with coronary heart disease. A 12-month follow-up. Gen Hosp Psychiatry 1996; 18(1): 61-5.
[http://dx.doi.org/10.1016/0163-8343(95)00100-X] [PMID: 8666215]
[5]
Kaufmann MW, Fitzgibbons JP, Sussman EJ, et al. Relation between myocardial infarction, depression, hostility, and death. Am Heart J 1999; 138(3 Pt 1): 549-54.
[http://dx.doi.org/10.1016/S0002-8703(99)70159-6] [PMID: 10467207]
[6]
Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003; 58(3): 249-65.
[http://dx.doi.org/10.1093/gerona/58.3.M249] [PMID: 12634292]
[7]
Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J 2003; 24(13): 1231-43.
[http://dx.doi.org/10.1016/S0195-668X(03)00201-X] [PMID: 12831818]
[8]
Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. London: Churchill Linvingston 2004.
[9]
Moss PA, Pettit JE. Platelets, blood coagulation and haemostasis.In: Hoffbrand AV, Ed Hoffbrant’s essential haematology. 7th ed. New Jersey: Wiley 2016; pp. 264-77.
[10]
David P. Steensma. Thrombosis 2: treatment. In: Hoffbrand AV, Ed. Hoffbrant’s essential haematology, 7th Ed. New Jersey: Wiley 2016; pp. 311-320..
[11]
Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(1)(Suppl.): 8S-21S.
[http://dx.doi.org/10.1378/chest.119.1_suppl.8S] [PMID: 11157640]
[12]
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest. 126(3 Suppl): 204S-233S..
[13]
Thakkar AN, Bendkhale SR, Taur SR, Gogtay NJ, Thatte UM. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurol India 2012; 60(6): 577-80.
[http://dx.doi.org/10.4103/0028-3886.105189] [PMID: 23287317]
[14]
Duncan D, Sayal K, McConnell H, Taylor D. Antidepressant interactions with warfarin. Int Clin Psychopharmacol 1998; 13(2): 87-94.
[http://dx.doi.org/10.1097/00004850-199803000-00006] [PMID: 9669190]
[15]
Ottervanger JP, Stricker BH, Huls J, Weeda JN. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151(5): 781-2.
[http://dx.doi.org/10.1176/ajp.151.5.781] [PMID: 8166328]
[16]
de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319(7217): 1106-9.
[http://dx.doi.org/10.1136/bmj.319.7217.1106] [PMID: 10531103]
[17]
Sarma A, Horne MK III. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol 2006; 77(6): 533-7.
[http://dx.doi.org/10.1111/j.0902-4441.2006.t01-1-EJH2919.x] [PMID: 16978240]
[18]
Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66(1): 76-81.
[http://dx.doi.org/10.1111/j.1365-2125.2008.03154.x] [PMID: 18460039]
[19]
Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18(5): 412-6.
[http://dx.doi.org/10.1002/pds.1737] [PMID: 19301238]
[20]
Komen JJ, Hjemdahl P, Mantel-Teeuwisse AK, Klungel OH, Wettermark B, Forslund T. Concomittant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study. ESC Congress 2019 together with World Congress of Cardilogy. 31 August- 4 September 2019; Paris, France. P4745. 2019..
[21]
van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323(7314): 655-8.
[http://dx.doi.org/10.1136/bmj.323.7314.655] [PMID: 11566827]
[22]
Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163(1): 59-64.
[http://dx.doi.org/10.1001/archinte.163.1.59] [PMID: 12523917]
[23]
Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164(21): 2367-70.
[http://dx.doi.org/10.1001/archinte.164.21.2367] [PMID: 15557417]
[24]
Abdelmalik N, Ruhé HG, Barwari K, et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 2008; 6(12): 2168-74.
[http://dx.doi.org/10.1111/j.1538-7836.2008.03196.x] [PMID: 18983505]
[25]
Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 2009; 29(4): 368-71.
[http://dx.doi.org/10.1097/JCP.0b013e3181abdfd7] [PMID: 19593177]
[26]
Allen SN, John S, Shannon J, Ferrara J. Treatment of depression in patients on anticoagulation therapy: antidepressant-warfarin drug interactions. US Pharm 2013; 38(11): 23-6.
[27]
Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168(2): 180-5.
[http://dx.doi.org/10.1001/archinternmed.2007.32] [PMID: 18227365]
[28]
Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23(7): 937-44.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02859.x] [PMID: 16573796]
[29]
Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119(2): 113-6.
[http://dx.doi.org/10.1016/j.amjmed.2005.03.044] [PMID: 16443409]
[30]
de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65(7): 795-803.
[http://dx.doi.org/10.1001/archpsyc.65.7.795] [PMID: 18606952]
[31]
Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit 2011; 33(4): 433-8.
[http://dx.doi.org/10.1097/FTD.0b013e318224996e] [PMID: 21743381]
[32]
Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 2011; 6(6)e21447
[http://dx.doi.org/10.1371/journal.pone.0021447] [PMID: 21731754]
[33]
Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol 2014; 114(4): 583-6.
[http://dx.doi.org/10.1016/j.amjcard.2014.05.037] [PMID: 25001151]
[34]
Löppönen P, Tetri S, Juvela S, et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. J Neurosurg 2014; 120(6): 1358-63.
[http://dx.doi.org/10.3171/2013.12.JNS131898] [PMID: 24506245]
[35]
Renoux C, Vahey S, Dell’Aniello S, Boivin JF. Association of selective serotonin reuptake inhibitors with risk for spontaneous intracranial hemorrhage. JAMA Neurol 2017; 74(2): 173-80.
[http://dx.doi.org/10.1001/jamaneurol.2016.4529] [PMID: 27918771]
[36]
Comoretto RI, Rea F, Lucenteforte E, et al. Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018; 74(8): 1061-70.
[http://dx.doi.org/10.1007/s00228-018-2467-8] [PMID: 29736825]
[37]
Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005; 25(6): 561-4.
[http://dx.doi.org/10.1097/01.jcp.0000186869.67418.bc] [PMID: 16282838]
[38]
Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72(9): 835-47.
[http://dx.doi.org/10.4065/72.9.835] [PMID: 9294531]
[39]
Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85(1): 11-28.
[http://dx.doi.org/10.1016/S0163-7258(99)00048-0] [PMID: 10674711]
[40]
Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44(5): 495-8.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00601.x] [PMID: 9384467]
[41]
Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 1999; 54(12): 947-51.
[http://dx.doi.org/10.1007/s002280050580] [PMID: 10192756]
[42]
Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40(8): 587-603.
[http://dx.doi.org/10.2165/00003088-200140080-00003] [PMID: 11523725]
[43]
Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27(3): 175-90.
[http://dx.doi.org/10.2165/00003088-199427030-00002] [PMID: 7988100]
[44]
Luvox CR. (fluvoxamine) package insert. Jazz Takeda Pharmaceuticals, Palo Alto CA 2011; https://www.accessdata. fda.gov/drugsatfda_docs/label/2011/022033s003lbl.pdf Revised May 2011. Available at: . https://www.accessdata.fda.gov/drugsatfda_ docs/label/2011/022033s003lbl.pdf
[45]
Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32(4): 313-34.
[http://dx.doi.org/10.2165/00003495-198632040-00002] [PMID: 3096686]
[46]
van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29(Suppl. 1): 1-9.
[http://dx.doi.org/10.2165/00003088-199500291-00003] [PMID: 8846617]
[47]
Yap KB, Low ST. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J 1999; 40(7): 480-2.
[PMID: 10560276]
[48]
Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. Ann Pharmacother 2002; 36(12): 1890-2.
[http://dx.doi.org/10.1345/aph.1C112] [PMID: 12452751]
[49]
Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metab Dispos 2013; 41(12): 2056-65.
[http://dx.doi.org/10.1124/dmd.113.052639] [PMID: 23785064]
[50]
Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM. Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000; 102(4): 250-5.
[http://dx.doi.org/10.1034/j.1600-0447.2000.102004250.x] [PMID: 11089724]
[51]
Sansone RA, Sansone LA. Warfarin and antidepressants: happiness without hemorrhaging. Psychiatry (Edgmont Pa) 2009; 6(7): 24-9.
[PMID: 19724766]
[52]
Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. II. J Clin Psychopharmacol 1990; 10(3): 213-7.
[http://dx.doi.org/10.1097/00004714-199006000-00011] [PMID: 2198298]
[53]
Claire RJ, Servis ME, Cram DL Jr. Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry 1991; 148(11): 1604.
[http://dx.doi.org/10.1176/ajp.148.11.1604a] [PMID: 1928485]
[54]
Woolfrey S, Gammack NS, Dewar MS, Brown PJ. Fluoxetine-warfarin interaction. BMJ 1993; 307(6898): 241.
[http://dx.doi.org/10.1136/bmj.307.6898.241-b] [PMID: 8369688]
[55]
Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997; 17(1): 170-2.
[PMID: 9017779]
[56]
Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46(3 Pt 2): 14-9.
[PMID: 3871765]
[57]
Ford MA, Anderson ML, Rindone JP, Jaskar DW. Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin. J Clin Psychopharmacol 1997; 17(2): 110-2.
[http://dx.doi.org/10.1097/00004714-199704000-00009] [PMID: 10950474]
[58]
Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci 1978; 23(8): 807-11.
[http://dx.doi.org/10.1016/0024-3205(78)90515-5] [PMID: 309056]
[59]
Dong YH, Bykov K, Choudhry NK, et al. Clinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors. a multidatabase observational cohort study. J Clin Psychopharmacol 2017; 37(2): 200-9.
[http://dx.doi.org/10.1097/JCP.0000000000000658] [PMID: 28129313]
[60]
Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmcokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80(Suppl. 350): 60-75.
[http://dx.doi.org/10.1111/j.1600-0447.1989.tb07176.x]]
[61]
Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11(4): 275-83.
[http://dx.doi.org/10.1016/S0924-977X(01)00101-8] [PMID: 11532381]
[62]
Jornil J, Jensen KG, Larsen F, Linnet K. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 2010; 38(3): 376-85.
[http://dx.doi.org/10.1124/dmd.109.030551] [PMID: 20007670]
[63]
Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009; 86(4): 425-9.
[http://dx.doi.org/10.1038/clpt.2009.95] [PMID: 19587643]
[64]
Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand Suppl 1989; 350: 102-6.
[http://dx.doi.org/10.1111/j.1600-0447.1989.tb07186.x] [PMID: 2530759]
[65]
Sjöqvist F. Drug interactionsFASS 2005 (the Swedish Physicians’ Desk Reference) 2005.
[66]
Ronfeld RA, Shaw GL, Tremaine LM. Distribution and pharmacokinetics of the selective 5-HT uptake blocker sertraline in man, rat, and dog. Psychopharmacology (Berl) 1988; 96(Suppl.): 269.
[67]
Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32(Suppl. 1): 37-42.
[http://dx.doi.org/10.2165/00003088-199700321-00006] [PMID: 9068934]
[68]
Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65(4): 573-9.
[http://dx.doi.org/10.1111/j.1365-2125.2007.03064.x] [PMID: 18070216]
[69]
Piatkov I, Rochester C, Jones T, Boyages S. Warfarin toxicity and individual variability-clinical case. Toxins (Basel) 2010; 2(11): 2584-92.
[http://dx.doi.org/10.3390/toxins2112584] [PMID: 22069565]
[70]
Wilner KD, Lazar JD, Apseloff G, Gerber N, Yurkewick L. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers. Biol Psychiatry 1991; 29: 354-5.
[71]
Schulman S, Elbazi R, Zondag M, O’Donnell M. Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J 2008; 6: 15.
[http://dx.doi.org/10.1186/1477-9560-6-15] [PMID: 18925967]
[72]
Perry CM, Benfield P. Sertraline: an overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 1997; 7: 480-500.
[http://dx.doi.org/10.2165/00023210-199707060-00008]]
[73]
Pfizer Inc. Zoloft (sertraline hydrochloride) package insert. Pfizer Inc, New York, NY; 2006.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839S74S86S87_20990S35S44S45lbl. pdfAvailable at:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839S74S86S87_20990S35S44S45lbl.pdf
[74]
Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51(1): 73-8.
[http://dx.doi.org/10.1007/s002280050163] [PMID: 8880055]
[75]
Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44(2): 199-202.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00628.x] [PMID: 9278211]
[76]
Lapatto-Reiniluoto O, Patinen L, Niemi M, Backman JT, Neuvonen PJ. Drug-related inadvert deaths in a university hospital- a declining trend. Basic Clin Pharmacol Toxicol 2015; 117(6): 421-6.
[http://dx.doi.org/10.1111/bcpt.12435] [PMID: 26111726]
[77]
von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29(8): 1102-9.
[PMID: 11454728]
[78]
Leiker LL, Mehta BH, Pruchnicki MC, Rodis JL. Risk factors and complications of subconjunctival hemorrhages in patients taking warfarin. Optometry 2009; 80(5): 227-31.
[http://dx.doi.org/10.1016/j.optm.2008.10.018] [PMID: 19410227]
[79]
Moffett BS, Kim S, Bomgaars LR. Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge. Pediatr Blood Cancer 2013; 60(9): 1503-6.
[http://dx.doi.org/10.1002/pbc.24546] [PMID: 23606286]
[80]
Bachawati M. Anticoagulation and psychotropic medications. Curr Psychiatry Rep 2010; 12(3): 265-71.
[http://dx.doi.org/10.1007/s11920-010-0120-z] [PMID: 20425290]
[81]
Dalton SO, Sørensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006; 20(2): 143-51.
[http://dx.doi.org/10.2165/00023210-200620020-00005] [PMID: 16478289]
[82]
Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997; 43(6): 619-26.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00591.x] [PMID: 9205822]
[83]
Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16(3)(Suppl. 2): 37S-50S.
[http://dx.doi.org/10.1097/00004714-199606002-00009] [PMID: 8784647]
[84]
Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo) 2012; 10(1): 110-5.
[http://dx.doi.org/10.1590/S1679-45082012000100024] [PMID: 23045839]
[85]
Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7(1)(Suppl. 1): 24-32.
[http://dx.doi.org/10.1002/(SICI)1520-6394(1998)7:1+<24:AID-DA7>3.0.CO;2-F] [PMID: 9597349]
[86]
Efexor package insert. Philadelpia, Pa: Wyeth Pharmaceuticals Inc; 2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdfJanuary 2017. Available at:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdf
[87]
Lilly USA. LLC Cymbalta package insert Indianapolis, IN 2011.Pi.lilly.com/us/cymbalta-pi.pdfAvailable at: . http://pi.lilly. com/us/cymbalta-pi.pdf
[88]
Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005; 27(8): 1126-43.
[http://dx.doi.org/10.1016/j.clinthera.2005.08.010] [PMID: 16199241]
[89]
Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005; 4(6): 987-93.
[http://dx.doi.org/10.1517/14740338.4.6.987] [PMID: 16255658]
[90]
Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol 2009; 49(12): 1456-66.
[http://dx.doi.org/10.1177/0091270009344335] [PMID: 19793910]
[91]
Glueck CJ, Khalil Q, Winiarska M, Wang P. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 2006; 295(13): 1517-8.
[http://dx.doi.org/10.1001/jama.295.13.1517] [PMID: 16595756]
[92]
Gimenez C, Guce G, Lingisetty C, Bernhardt L. Severe INR elevation related to duloxetine use: a case report. Psychosomatics 2011; 52(6): 583-5.
[http://dx.doi.org/10.1016/j.psym.2011.06.001] [PMID: 22054632]
[93]
European Medicines Agency http://www.emea.europa.eu/Available at:. https://www.ema.europa.eu/en
[94]
Monastero R, Camarda R, Camarda C. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer’s disease. Clin Ther 2007; 29(12): 2706-9.
[http://dx.doi.org/10.1016/j.clinthera.2007.12.026] [PMID: 18201587]
[95]
Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44(9): 977-88.
[http://dx.doi.org/10.2165/00003088-200544090-00007] [PMID: 16122284]
[96]
Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009; 37(10): 2045-54.
[http://dx.doi.org/10.1124/dmd.109.028274] [PMID: 19608694]
[97]
Sawamura J, Kozaki K, Mochizuki S, Ishigooka J. Possible interaction between milnacipran and warfarin potassium. J Clin Pharmacol 2012; 52(5): 780-1.
[http://dx.doi.org/10.1177/0091270011398244] [PMID: 22539653]
[98]
Cheng YL, Hu HY, Lin XH, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding. A nationwide population-based cohort study in Taiwan. Medicine (Baltimore) 2015; 94(46)e2022
[http://dx.doi.org/10.1097/MD.0000000000002022] [PMID: 26579809]
[99]
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151(6): 737-48.
[http://dx.doi.org/10.1038/sj.bjp.0707253] [PMID: 17471183]
[100]
Loomis CW, Racz WJ. Drug interactions of amitriptyline and nortriptyline with warfarin in the rat. Res Commun Chem Pathol Pharmacol 1980; 30(1): 41-58.
[PMID: 7433768]
[101]
Pond SM, Graham GG, Birkett DJ, Wade DN. Effects of tricyclic antidepressants on drug metabolism. Clin Pharmacol Ther 1975; 18(2): 191-9.
[http://dx.doi.org/10.1002/cpt1975182191] [PMID: 50160]
[102]
Strain JJ, Caliendo G, Alexis JD, Karim A, Loigman M. LoweIII RS. Cardiac drug and psychotropic drug interactions: significance and recommendations. Heart Dis 2001; 3(4): 248-62.
[http://dx.doi.org/10.1097/00132580-200107000-00008] [PMID: 11975802]
[103]
Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995; 29(5): 292-332.
[http://dx.doi.org/10.2165/00003088-199529050-00002] [PMID: 8582117]
[104]
Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57(6): 670-7.
[http://dx.doi.org/10.1016/0009-9236(95)90230-9] [PMID: 7781267]
[105]
Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41(8): 619-28.
[http://dx.doi.org/10.1080/07853890903186168] [PMID: 19711211]
[106]
Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36(Suppl. 5): S8-S13.
[http://dx.doi.org/10.1111/j.1528-1157.1995.tb06007.x] [PMID: 8806399]
[107]
Dahl ML, Voortman G, Alm C, Elwin CE, Delbressine L, Vos R, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Investig 1997; 13: 37-46.
[http://dx.doi.org/10.2165/00044011-199713010-00005]]
[108]
Norton J, Quarles E. Mirtazapine-induced warfarin toxicity. Prim Psychiatry 2002; 9: 30-1.
[109]
Nishimura H, Kawakami M. A case with increased PT-INR after the addition of mirtazapine to warfarin therapy. Seishin Shinkeigaku Zasshi 2015; 117(10): 820-5.
[PMID: 26827407]
[110]
Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278(1): 21-30.
[PMID: 8764331]
[111]
Warwick HMC, Mindham RHS. Concomitant administration of mianserin and warfarin. Br J Psychiatry 1983; 143: 308.
[http://dx.doi.org/10.1192/S0007125000117635] [PMID: 6626845]
[112]
Shelley RK. Mianserin and warfarin. Br J Psychiatry 1984; 145: 97-8.
[http://dx.doi.org/10.1192/S0007125000204510] [PMID: 6743958]
[113]
Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26(6): 572-5.
[PMID: 9616194]
[114]
Jalili M, Dehpour AR. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids. Arch Med Res 2007; 38(8): 901-4.
[http://dx.doi.org/10.1016/j.arcmed.2007.05.004] [PMID: 17923275]
[115]
Hardy JL, Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone. CMAJ 1986; 135(12): 1372.
[PMID: 3779574]
[116]
Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother 2000; 34(6): 734-6.
[http://dx.doi.org/10.1345/aph.19336] [PMID: 10860134]
[117]
Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25(3): 226-9.
[http://dx.doi.org/10.1097/01.jcp.0000162805.46453.e3] [PMID: 15876900]
[118]
Bavle AD, Phatak AS. Bupropion-warfarin combination: a serious complication. Indian J Psychol Med 2013; 35(3): 311-3.
[http://dx.doi.org/10.4103/0253-7176.119488] [PMID: 24249938]
[119]
Wienkers LC, Allievi C, Hauer MJ, Wynalda MA. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27(11): 1334-40.
[PMID: 10534319]
[120]
Outhoff K. Agomelatine: a review for general practitioners. S Afr Fam Pract 2012; 54(3): 181-7.
[http://dx.doi.org/10.1080/20786204.2012.10874212]]
[121]
Khan A, Sambunaris A, Edwards J, Ruth A, Robinson DS. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol 2014; 29(2): 86-92.
[http://dx.doi.org/10.1097/YIC.0000000000000016] [PMID: 24247740]
[122]
Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011; 25(7): 615-27.
[http://dx.doi.org/10.2165/11207550-000000000-00000] [PMID: 21699273]
[123]
Viibryd (vilazodone HCl) package insert. Irvine, CA Allergan USA, Inc, 2017 (Revised); 2017.https://www.allergan.com/assets/pdf/viibryd_piAvailable at:. https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/2018-05-8-Viibryd(vilazodone)-USPI-Clean.pdf
[124]
Wang Y, Wojtkowski T, Hanson E, Harris S, Karim A. An open-label, multiple-dose study in healthy adults to assess the drug interaction potential of Lu AA21004 using the Indiana cocktail. J Clin Pharmacol 2009; 49(9): 1114.
[PMID: 19620385]
[125]
Brintellix (vortioxetine) package insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc 2013 September;; https://www. accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdfAvailable at: . https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
[126]
Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol 2015; 55(6): 671-9.
[http://dx.doi.org/10.1002/jcph.456] [PMID: 25641606]
[127]
Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27(1): 31-40.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03541.x] [PMID: 17919277]
[128]
de Abajo FJ, Montero D, Rodríguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98(3): 304-10.
[http://dx.doi.org/10.1111/j.1742-7843.2006.pto_303.x] [PMID: 16611206]

Rights & Permissions Print Cite
Article Metrics
8
1
© 2024 Bentham Science Publishers | Privacy Policy